Our Pricing

Wegovy vs Ozempic Differences: Online Prescription

Published on: June 03, 2026

Understanding wegovy vs ozempic uk online prescription options is essential for patients seeking semaglutide treatment. While both medications contain the same active ingredient, they differ significantly in licensed indications, dosing schedules, and clinical outcomes. At Cured Pharmacy, our UK-registered prescribers assess your eligibility for either treatment through a free online consultation, with Wegovy available from £79.00.

The Core Difference: Wegovy vs Ozempic Licensing and Dosing

Both Wegovy and Ozempic contain semaglutide, a GLP-1 receptor agonist that mimics a natural hormone regulating appetite and blood sugar. However, the MHRA has licensed these medications for different purposes: Ozempic is approved for type 2 diabetes management at doses up to 1mg weekly, while Wegovy is specifically licensed for chronic weight management at higher doses reaching 2.4mg weekly [1].

This distinction matters clinically. In the STEP 1 trial, participants using Wegovy at the full 2.4mg dose achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [1]. Ozempic, when prescribed off-label for weight loss at lower diabetes-approved doses, typically produces more modest weight reduction outcomes.

The dosing escalation also differs. Wegovy follows a structured five-month titration schedule (0.25mg, 0.5mg, 1mg, 1.7mg, then 2.4mg maintenance), allowing your body to adapt gradually and minimising gastrointestinal side effects [2]. Ozempic uses a shorter titration appropriate for diabetes management but not optimised for weight loss goals.

Clinical Evidence: Weight Loss Outcomes Compared

The STEP clinical trial programme provides robust evidence for Wegovy's efficacy in weight management. Across multiple studies involving over 4,500 participants, those receiving Wegovy 2.4mg weekly lost significantly more weight than control groups, with 50.5% of participants achieving at least 15% body weight reduction [1][2].

Ozempic's weight loss data comes primarily from cardiovascular outcome trials in diabetic populations, not dedicated obesity studies. The SUSTAIN trials demonstrated weight reduction as a secondary outcome, but at lower doses than Wegovy's maintenance regimen. Patients seeking weight management specifically benefit from Wegovy's higher dosing and obesity-focused licensing.

Both medications work through the same mechanism—activating GLP-1 receptors to slow gastric emptying, reduce appetite, and improve insulin sensitivity—but the dose-response relationship means higher semaglutide exposure generally produces greater weight loss, subject to individual tolerance and prescriber assessment [3].

Real-World Effectiveness

Beyond controlled trials, real-world UK data shows that patients prescribed Wegovy at the full maintenance dose maintain better adherence and achieve more sustained weight loss compared to off-label Ozempic use for weight management. Your UK prescriber will consider your medical history, weight loss goals, and any contraindications when recommending the most appropriate semaglutide treatment.

Side Effects and Safety Profile

Because Wegovy and Ozempic contain the same active ingredient, their side effect profiles overlap substantially. The most common adverse effects are gastrointestinal: nausea, diarrhoea, vomiting, constipation, and abdominal discomfort. These typically occur during dose escalation and diminish as your body adapts [2][3].

The higher maintenance dose of Wegovy may increase the frequency or intensity of these side effects compared to lower Ozempic doses. In STEP trials, approximately 44% of Wegovy users experienced nausea, though most cases were mild to moderate and resolved within weeks [1]. Proper titration and dietary adjustments can significantly reduce gastrointestinal symptoms.

Both medications carry similar warnings regarding thyroid C-cell tumours (observed in rodent studies, not confirmed in humans), pancreatitis risk, and gallbladder disease. Your UK prescriber will screen for personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 before prescribing either medication. Neither should be used during pregnancy or breastfeeding [3].

Managing Common Side Effects

Practical strategies include eating smaller meals, avoiding high-fat foods, staying well-hydrated, and injecting at consistent times. If side effects persist or worsen, contact your prescriber—dose adjustments or additional support may be appropriate. Never increase your dose faster than the prescribed schedule, as this significantly increases adverse effect risk.

Cost and Availability: Wegovy vs Ozempic UK Pricing

Wegovy is available at Cured Pharmacy from £79.00 per pen, with transparent upfront pricing shown before your consultation. We guarantee the lowest UK prices and offer discreet next-day delivery across the United Kingdom. Your final cost depends on the prescribed dose and treatment duration determined by your UK prescriber.

Ozempic pricing varies depending on whether it's prescribed for diabetes or weight management. Because Wegovy is specifically licensed for weight loss, most UK prescribers prefer it for obesity treatment, ensuring appropriate dosing and regulatory compliance. Some patients initially prescribed Ozempic for diabetes may experience weight loss as a beneficial secondary effect.

NHS availability for weight-loss medications remains limited, with strict eligibility criteria typically requiring BMI over 35 with comorbidities or BMI over 40. Private prescription through regulated UK online pharmacies like Cured Pharmacy offers faster access, with consultations completed in under three minutes and medications dispatched the same day when approved before our cut-off time.

How to Get a Wegovy vs Ozempic Prescription Online

Obtaining a prescription through Cured Pharmacy involves a straightforward three-step process. First, complete our free online consultation questionnaire, which takes under three minutes and covers your medical history, current medications, weight loss goals, and any contraindications. This information is reviewed by our UK-registered prescribers, supervised by Superintendent Pharmacist Tarun Kumar (GPhC 2233073).

Second, a qualified UK prescriber assesses your eligibility for semaglutide treatment, determining whether Wegovy or another weight management option best suits your clinical profile. They'll consider factors including your BMI, previous weight loss attempts, cardiovascular risk factors, and any diabetes diagnosis. All prescription decisions comply with MHRA guidelines and NICE recommendations [4].

Third, if approved, your medication is dispensed from our GPhC-registered pharmacy (9012511) and dispatched in 100% discreet packaging. We supply only genuine UK-licensed medicines, never grey-market imports. You'll receive clear injection instructions, titration guidance, and access to our clinical team for ongoing support throughout your treatment journey.

Consultation Requirements

Your online assessment must include accurate information about any history of pancreatitis, thyroid conditions, diabetic retinopathy, kidney disease, or eating disorders. Withholding medical information compromises your safety and may result in inappropriate prescribing. Our prescribers cannot approve treatment if you're pregnant, breastfeeding, or planning pregnancy within the treatment timeframe.

Which Treatment Is Right for You: Wegovy vs Ozempic Decision Guide

If your primary goal is weight loss and you don't have type 2 diabetes, Wegovy represents the evidence-based choice. Its licensing specifically for chronic weight management, higher maintenance dose, and robust clinical trial data in obesity populations make it the preferred semaglutide option for weight reduction [1][2].

Patients with type 2 diabetes seeking both glycaemic control and weight loss may be prescribed Ozempic, though some prescribers now favour Wegovy even in diabetic patients when weight management is the priority. Your prescriber will consider your HbA1c levels, diabetes medication regimen, and overall metabolic health when making this determination.

Neither medication is suitable for everyone. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, previous severe allergic reaction to semaglutide, and diabetic ketoacidosis. Your UK prescriber will conduct a thorough assessment to ensure safe, appropriate prescribing aligned with your individual health profile [3][4].

Long-Term Treatment Considerations

Semaglutide treatments work best as part of a comprehensive weight management programme including dietary modifications and increased physical activity. Clinical trials show that weight regain commonly occurs after discontinuation, so your prescriber will discuss realistic treatment duration and maintenance strategies. Regular follow-up ensures ongoing appropriateness and allows dose adjustments based on your response and tolerability.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
3. Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy and Ozempic are prescription-only medicines containing semaglutide, licensed by the MHRA for different indications. Individual results may vary, and weight loss outcomes depend on multiple factors including diet, exercise, and adherence to treatment. Never share your medication with others or use semaglutide obtained without a valid UK prescription.